Measuring prevalence of high risk medicines use in community pharmacies

Safe dispensing indicators:

Indicator Description of conditions

1. Warfarin and INR monitoring

1. Number of patients dispensed a prescription for warfarin AND

2. Whose latest INR result is not recorded in the pharmacy’s Patient Medication Record (PMR) system

2. Dosing instructions for methotrexate

1. Number of patients dispensed a prescription for methotrexate AND

2. The prescription contains no or non-specific directions for use (e.g. “to be taken as directed”)

3. Verapamil in combination with beta-blockers

1. Number of patients dispensed a prescription for verapamil AND

2. Who are also dispensed a prescription for a beta-blocker

4. Use of valproate in girls and women of childbearing potential (1)

1. Number of patients dispensed a prescription for sodium valproate or valproic acid AND

2. Who are female AND

3. Who are aged between 13 and 45

5. Use of valproate in girls and women of childbearing potential (2)

Of the patients identified in number 4, the number who have been provided the patient information booklet.

6. Over 65s prescribed an antipsychotic medicine

1. Numbers of patients dispensed prescriptions for antipsychotic medicine AND

2. Where the patient is aged 65 or over

7. Warfarin and oral NSAIDs

1. Number of patients dispensed a prescription for warfarin AND

2. Who are also dispensed a prescription for an oral Non-Steroidal Anti-Inflammatory Drug (NSAID)

8. NSAIDs in combination with aspirin or clopidogrel without gastroprotection

1. Number of patients dispensed a prescription for an NSAID AND

2. Who are dispensed a prescription for aspirin or clopidogrel AND

3. Who are not dispensed a prescription for suitable gastroprotection (PPI or H2 antagonist) AND

4. Are aged 65 or over

9. Excessive use of short acting bronchodilators in asthma

1. Number of patients who have been dispensed prescriptions or received emergency supplies (combined total) of more than 6 inhaled short acting beta agonists in the previous 6 months AND

2. Who have not been prescribed an inhaled corticosteroid in the previous 6 months

 

Submission date

Period to which data relates

Indicators

Between 1 and 31 May 2019

April 2019

1 to 5

Between 1 and 31 August 2019

July 2019

6 to 9

Between 1 and 30 November 2019

October 2019

1 to 5

Between 1 February and 28 February 2020

January 2020

6 to 9

Data will be submitted through NECAF and the data submission screen will be open only for the dates shown.

http://www.cpwales.org.uk/Services-and-commissioning/Quality-Scheme/High-Risk-Medicines-Survey.aspx